Technology Listings

Inhibitors of Human Carbonic Anhydrase II


Potent carbonic anhydrase II (CAII) inhibitors for drug discovery and a method for designing them.

Key Benefits
  • Highly potent molecules for inhibiting carbonic anhydrase.
  • Compounds generated using a novel computational chemistry method based on a validated data retrieval platform.
Market Summary

Obesity is a chronic medical condition and is commonly associated with type 2 diabetes, hypertension, dyslipidemia, and coronary heart disease. Few medications are available for the management of obesity. Currently, the 3 major groups of drugs target the impairment of dietary intake, impairment of dietary absorption, and/or increased energy expenditure. Carbonic anhydrases (CA) are enzymes present in all organisms and are responsible for catalyzing CO2 hydration to bicarbonate and protons. The inhibition of carbonic anhydrase II enzymes may be a potential target for treatment of ocular hypertension and obesity.

Technical Summary

Researchers have shown that, in many organisms, carbonic anhydrase (CA) enzymes are involved in physiological processes connected with respiration, CO2 transport, pH, electrolyte secretion and others. Emory inventors have developed highly potent compounds for the inhibition of CAII. These compounds were generated using a computational chemistry method the investigators have named FRESH (Fragment-based Exploitation of modular Synthesis by vHTS). These CAII inhibitor compounds have therapeutic potential in several conditions including obesity and ocular hypertension.

Developmental Stage

Carbonic anhydrase II inhibitors have been developed

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
PCT PCT PCT/US2016/024179   3/25/2016    
Tech ID: 15054
Published: 6/22/2015
Drug Discovery

Cale Lennon
Director, Licensing
Emory University

James Snyder
Qi Shi
Thomas Kaiser
Zachary Dentmon

Metabolic Diseases